Resveratrol und Parodontitis

Die Studienlage zu Resveratrol im Bezug auf parodontale Erkrankungen ist noch jung, jedoch bereits sehr aussagekräftig. Die wichtigsten Studien, welche unter anderem entscheidend für die Konfiguration von ParoStop Repair and Protect waren, haben wir hier für Sie zusammengetragen.

Wir verwenden Resveratrol in Verbindung mit essentiellen Co- Faktoren, Made in Germany und mit maximaler Bioverfügbarkeit.

https://pubmed.ncbi.nlm.nih.gov/31035477/

https://www.sciencedirect.com/science/article/abs/pii/S2212429221003308

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612209/

https://encyclopedia.pub/entry/14412

https://www.mountsinai.on.ca/care/dentistry/centre-for-advanced-dental-research-and-care/research/resveratrol-curumin-aoda.pdf

https://www.mountsinai.on.ca/care/dentistry/centre-for-advanced-dental-research-and-care/research/resveratrol-induces-healing-of-periodontitis-in.pdf

https://www.frontiersin.org/articles/10.3389/fdmed.2021.636423/full

Jarosova V, Vesely O, Marsik P, Jaimes JD, Smejkal K, Kloucek P, et al. Metabolism of stilbenoids by human faecal microbiota. Molecules. (2019) 24:1155. doi: 10.3390/molecules24061155

Wang P, and Sang S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. Biofactors. (2018) 44:16–25. doi: 10.1002/biof.1410

Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer. (2004) 90:736–44. doi: 10.1038/sj.bjc.6601568

Lin HS, Choo QY, and Ho PC. Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study. Biomed Chromatogr. (2010) 24:1373–8. doi: 10.1002/bmc.1454

Ben Lagha A, Andrian E, and Grenier D. Resveratrol attenuates the pathogenic and inflammatory properties of Porphyromonas gingivalis. Mol Oral Microbiol. (2019) 34:118–30. doi: 10.1111/omi.12260

Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. (2007) 16:1246–52. doi: 10.1158/1055-9965.EPI-07-0022

Whitlock NC, and Baek SJ. The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer. (2012) 64:493–502. doi: 10.1080/01635581.2012.667862